For instance, Lau et al. found that plasma I-FABP levels decrease in high-fat fed rats, while I-FABP expression in the jejunum appears to increase, indicating that I-FABP may not be an ideal marker for assessing intestinal barrier function in non-alcoholic fatty liver disease (NAFLD) [74]. Here, FABP2 is linked to metabolic dysfunction-associated steatotic liver disease.